Individuals with Down syndrome (DS) generally show neuropathological features of Alzheimer disease (AD). The trisomy of chromosome 21 causes an imbalance of antioxidant systems, which can be linked to AD pathophysiology.
Objective
Verify the difference between the activity of antioxidant enzymes and products of the oxidation process in peripheral blood in non-trisomic (NT) and trisomic (DS) adults and elders and respective associations with cognitive impairment.
Methods
A total of 120 subjects were included in this study. Sociodemographic and clinical information were collected as per protocol for participants in DS and NT groups. The cognitive state of the DS participants was established according to the Brazilian version of the Cambridge Examination for Mental Disorders of Older People with Down's syndrome and Others with Intellectual Disabilities (CAMDEX-DS). The CAMDEX interview was used for this purpose for participants in the NT group. Plasma samples were collected to evaluate protein carbonyl content, superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT), malondialdehyde (MDA), and 4-hydroxy-2-nonenal (HNE).
Results
We found increased levels of SOD and CAT activity in the DS group. When the groups were stratified by cognitive decline, elevated levels of SOD and CAT activity were found both in DS groups with and without decline. The activity of GPx was similar between the groups, as well as MDA and HNE.
Conclusion
The results suggest that alterations of the antioxidative processes can be implicated in the onset of neurodegeneration observed in individuals with DS.
AntonarakisSESkotkoBGRafiiMS, et al.Down syndrome. Nat Rev Dis Primers2020; 6: 9.
2.
SainiFDell’AcquaFStrydomA. Structural connectivity in Down syndrome and Alzheimer’s disease. Front Neurosci2022; 16: 908413.
3.
De França BramJMTalibLLJoaquimHPG, et al.Alzheimer’s disease-related biomarkers in aging adults with Down syndrome: systematic review. CPRR2019; 15: 49–57.
4.
MenéndezM. Down syndrome, Alzheimer’s disease and seizures. Brain Dev2005; 27: 246–252.
5.
ForteaJZamanSHHartleyS, et al.Alzheimer’s disease associated with Down syndrome: a genetic form of dementia. Lancet Neurol2021; 20: 930–942.
6.
HampelHHardyJBlennowK, et al.The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry2021; 26: 5481–5503.
7.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer’s disease. Lancet2021; 397: 1577–1590.
8.
Carmona-IraguiMVidelaLLleóA, et al.Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: the complex triangle of brain amyloidosis. Dev Neurobiol2019; 79: 716–737.
9.
TamagnoEGuglielmottoMVasciaveoV, et al.Oxidative stress and beta amyloid in Alzheimer’s disease. Which comes first: the chicken or the egg?Antioxidants2021; 10: 1479.
10.
SingulaniMPPereiraCPMFerreiraAFF, et al.Impairment of PGC-1α-mediated mitochondrial biogenesis precedes mitochondrial dysfunction and Alzheimer’s pathology in the 3xTg mouse model of Alzheimer’s disease. Exp Gerontol2020; 133: 110882.
ButterfieldDAGalvanVLangeMB, et al.In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid β-peptide of APP. Free Radic Biol Med2010; 48: 136–144.
13.
CaiZZhaoBRatkaA. Oxidative stress and β-amyloid protein in Alzheimer’s disease. Neuromol Med2011; 13: 223–250.
14.
WanLNieGZhangJ, et al.β-Amyloid peptide increases levels of iron content and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease. Free Radic Biol Med2011; 50: 122–129.
15.
BaiRGuoJYeX-Y, et al.Oxidative stress: the core pathogenesis and mechanism of Alzheimer’s disease. Ageing Res Rev2022; 77: 101619.
16.
LiuZLiTLiP, et al.The ambiguous relationship of oxidative stress, tau hyperphosphorylation, and autophagy dysfunction in Alzheimer’s disease. Oxid Med Cell Longev2015; 2015: 352723.
17.
JomovaKRaptovaRAlomarSY, et al.Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging. Arch Toxicol2023; 97: 2499–2574.
18.
CollinFCheignonCHureauC. Oxidative stress as a biomarker for Alzheimer’s disease. Biomark Med2018; 12: 201–203.
19.
TorresLLQuaglioNBDe SouzaGT, et al.Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis2011; 26: 59–68.
20.
RaniPKrishnanSRani CathrineC. Study on analysis of peripheral biomarkers for Alzheimer’s disease diagnosis. Front Neurol2017; 8: 328.
21.
PerroneSLonginiMBellieniCV, et al.Early oxidative stress in amniotic fluid of pregnancies with Down syndrome. Clin Biochem2007; 40: 177–180.
22.
PerluigiMButterfieldDA. Oxidative stress and Down syndrome: a route toward Alzheimer-like dementia. Curr Gerontol Geriatr Res2012; 2012: 724904.
23.
OlufunmilayoEOGerke-DuncanMBHolsingerRMD. Oxidative stress and antioxidants in neurodegenerative disorders. Antioxidants2023; 12: 517.
24.
RothMTymEMountjoyCQ. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry1986; 149: 698–709.
25.
FonsecaLMHaddadGGMattarGP, et al.The validity and reliability of the CAMDEX-DS for assessing dementia in adults with Down syndrome in Brazil. Braz J Psychiatry2019; 41: 225–233.
26.
GarletTRParisottoEBde MedeirosGdS, et al.Systemic oxidative stress in children and teenagers with Down syndrome. Life Sci2013; 93: 558–563.
27.
HeJLiTChenJ, et al.Plasma antioxidant enzymes and lipoperoxidation status in children with Down syndrome. Clin Biochem2016; 49: 61–65.
28.
NikolićABogavacMGrujićZ, et al.Disturbance of oxidative balance in the pregnancy with fetal trisomy 21. J Matern Fetal Neonatal Med2022; 35: 6080–6083.
29.
MuchováJSustrováMGaraiováI, et al.Influence of age on activities of antioxidant enzymes and lipid peroxidation products in erythrocytes and neutrophils of Down syndrome patients. Free Radic Biol Med2001; 31: 499–508.
30.
PercyMEDaltonAJMarkovicVD, et al.Red cell superoxide dismutase, glutathione peroxidase and catalase in down syndrome patients with and without manifestations of Alzheimer disease. Am J Med Genet1990; 35: 459–467.
31.
ZisPStrydomA. Clinical aspects and biomarkers of Alzheimer’s disease in Down syndrome. Free Radic Biol Med2018; 114: 3–9.
32.
García-BlancoABaqueroMVentoM, et al.Potential oxidative stress biomarkers of mild cognitive impairment due to Alzheimer disease. J Neurol Sci2017; 373: 295–302.
33.
CrawfordAFassettRGGeraghtyDP, et al.Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease. Gene2012; 501: 89–103.
34.
PeiJPanXWeiG, et al.Research progress of glutathione peroxidase family (GPX) in redoxidation. Front Pharmacol2023; 14: 1147414.
35.
NèveJSinetPMMolleL, et al.Selenium, zinc and copper in Down’s syndrome (trisomy 21): blood levels and relations with glutathione peroxidase and superoxide dismutase. Clin Chim Acta1983; 133: 209–214.
36.
CasadoALópez-FernándezMERuízR. Lipid peroxidation in Down syndrome caused by regular trisomy 21, trisomy 21 by Robertsonian translocation and mosaic trisomy 21. Clin Chem Lab Med2007; 45: 59–62.
37.
DeiRTakedaANiwaH, et al.Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer’s disease. Acta Neuropathol2002; 104: 113–122.
38.
CeniniGDowlingALSBeckettTL, et al.Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta2012; 1822: 130–138.
39.
LovellMAEhmannWDMattsonMP, et al.Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer’s disease. Neurobiol Aging1997; 18: 457–461.
40.
SultanaRPerluigiMNewmanSF, et al.Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer’s disease. Antioxid Redox Signal2010; 12: 327–336.
41.
ZabelMNackenoffAKirschWM, et al.Markers of oxidative damage to lipids, nucleic acids and proteins and antioxidant enzymes activities in Alzheimer’s disease brain: a meta-analysis in human pathological specimens. Free Radic Biol Med2018; 115: 351–360.
BaroneEHeadEButterfieldDA, et al.HNE-modified proteins in Down syndrome: involvement in development of Alzheimer disease neuropathology. Free Radic Biol Med2017; 111: 262–269.
44.
Di DomenicoFPupoGTramutolaA, et al.Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. Free Radic Biol Med2014; 71: 270–280.
45.
ZitnanováIKorytárPSobotováH, et al.Markers of oxidative stress in children with Down syndrome. Clin Chem Lab Med2006; 44: 306–310.
46.
GulesserianTSeidlRHardmeierR, et al.Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J Investig Med2001; 49: 41–46.
47.
GarcíaOFlores-AguilarL. Astroglial and microglial pathology in Down syndrome: focus on Alzheimer’s disease. Front Cell Neurosci2022; 16: 987212.
48.
GreberSLubecGCairnsN, et al.Decreased levels of synaptosomal associated protein 25 in the brain of patients with down syndrome and Alzheimer’s disease. In: DunnMJ (eds) From genome to proteome. Weinheim, Germany: Wiley-VCH Verlag GmbH, 2007, pp.348–354.
49.
ZdaniukGWierzba-BobrowiczTSzpakGM, et al.Astroglia disturbances during development of the central nervous system in fetuses with Down’s syndrome. Folia Neuropathol2011; 49: 109–114.
50.
ChenCJiangPXueH, et al.Role of astroglia in Down’s syndrome revealed by patient-derived human-induced pluripotent stem cells. Nat Commun2014; 5: 4430.
51.
Ponroy BallyBMuraiKK. Astrocytes in Down syndrome across the lifespan. Front Cell Neurosci2021; 15: 702685.
52.
PaganoGCastelloG. Oxidative stress and mitochondrial dysfunction in Down syndrome. Adv Exp Med Biol2012; 724: 291–299.
53.
SebastiàJCristòfolRPertusaM, et al.Down’s syndrome astrocytes have greater antioxidant capacity than euploid astrocytes. Eur J Neurosci2004; 20: 2355–2366.
54.
SpitzGHicksAJMcDonaldSJ, et al.Plasma biomarkers in chronic single moderate-severe traumatic brain injury. Brain2024; 147: 3690–3701.
55.
Flores-AguilarLIulitaMFKovecsesO, et al.Evolution of neuroinflammation across the lifespan of individuals with Down syndrome. Brain2020; 143: 3653–3671.
